Publications
Where expertise meets impact
Berry doesn’t just follow industry standards — we set them. Our team of award-winning statisticians, journal editors, and regulatory advisors leads the field in Bayesian and adaptive trial design. With research published in The New England Journal of Medicine, JAMA, and The Lancet, we’re driving innovation where it matters most.
Over 90% of our scientists published influential work this past year, advancing adaptive, Bayesian, and platform trial methodology. Our blend of academic rigor, regulatory insight, and real-world experience makes Berry a true authority in modern clinical trials.
Explore our most impactful peer-reviewed publications below.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
JAMA
Infectious Disease
COVID-19
Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial
March 22, 2022
2022
DOI: 10.1001/jama.2022.2910
Pharmaceutical Statistics
Methodology
Platform
Decision rules for identifying combination therapies in open-entry, randomized controlled platform trials
January 31, 2022
2022
doi.org/10.1002/pst.2194
JAMA
Infectious Disease
COVID-19
Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial
October 4, 2021
2021
DOI: 10.1001/jama.2021.18178
The New England Journal of Medicine
Infectious Disease
COVID-19
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19
August 4, 2021
2021
DOI: 10.1056/NEJMoa2103417
The New England Journal of Medicine
Infectious Disease
COVID-19
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19
August 4, 2021
2021
DOI: 10.1056/NEJMoa2105911
The Lancet
Infectious Disease
COVID-19
Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
July 27, 2021
2021
DOI: 10.1016/S2213-2600(21)00310-6
Nature Medicine
Neuroscience
Alzheimer's Disease
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease
July 27, 2021
2021
DOI: 10.1038/s41591-021-01369-8
Springer Nature
Infectious Disease
COVID-19
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial
July 12, 2021
2021
DOI: 10.1007/s00134-021-06448-5
No results found.
There are no results with this criteria. Try changing your search.